Previous 10 | Next 10 |
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET PR Newswire CUPERTINO, Calif. , May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced ...
Are These On Your List Of Penny Stocks To Watch This Week? As penny stocks come back into focus, investors are ready for a new month to begin. In May 2021, there are plenty of industries that traders may want to add to their penny stock watchlists. Right now, we see trends with tech, bi...
DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4 PR Newswire CUPERTINO, Calif. , April 27, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 202...
DURECT Corporation Announces Publication of DUR-928's Mechanism of Action -- DUR-928 is an inhibitor of DNA methyltransferases (DNMTs) regulating expression of genes involved in cell survival, inflammation and lipid biosynthesis -- Mechanism of action supports development of...
DURECT Corporation (DRRX) Q4 2020 Earnings Conference Call March 04, 2021, 04:30 PM ET Company Participants Mike Arenberg - CFO Jim Brown - President & CEO WeiQi Lin - EVP, Research & Development & Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Particip...
DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs Webcast of Earnings Call Today, March 4th at 4:30 p.m. Eastern Time PR Newswire CUPERTINO, Calif. , March 4, 2021 /PRNewswire/ -- DURECT Corporation (N...
DURECT Corporation to Participate in Three Investor Conferences in March 2021 PR Newswire CUPERTINO, Calif. , March 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferenc...
DURECT Corporation to Announce 2020 Financial Results and Provide Business Update on March 4 PR Newswire CUPERTINO, Calif. , Feb. 25, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended ...
Durect has been all over the place, but its AH indication is the one that looks like its best bet. Phase 2a data was very positive. However, phase 2b pivotal data is 2 years away. For further details see: Durect: Positive Data In Alcoholic Hepatitis, But Catalysts Too Fa...
DURECT ([[DRRX]] -15.5%) priced its earlier announced underwritten public offering of 17.7M shares for gross proceeds of ~$42.5M.Underwriters granted 30-day option to to purchase up to an additional 2.66M shares.Proceeds to be used for general corporate purposes, which may include clinical tr...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...